RIVAROXABAN | A213114 | MACLEODS PHARMACEUTICALS LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Bayer Pharma AG et al v. Macleods Pharmaceuticals Ltd. et al 1 patentANDA 213114rivaroxaban | D. Del. | 2025-06-09 | Terminated 2025-12-11 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.7967
per ea
Lowest NADAC/Unit
$0.7967
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 33342048809RIVAROXABAN 2.5 MG TABLET | $0.7967 | EA | Generic | — | 2026-06-17 |
| 33342048857RIVAROXABAN 2.5 MG TABLET | $0.7967 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.